Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
MyMD Pharmaceuticals, Inc. (AKER) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application for Phase 2 Study of oral TNF-α inhibitor MYMD-1 ® in Rheumatoid Arthritis"
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Operator"
08/01/2023 8-K Quarterly results
07/31/2023 8-K Quarterly results
07/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/14/2023 8-K Other Events  Interactive Data
06/30/2023 ARS Form ARS - Annual Report to Security Holders:
06/30/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/09/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Third AMENDMENT TO EMPLOYMENT AGREEMENT"
03/22/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/22/2023 8-K Other Events  Interactive Data
03/20/2023 8-K Quarterly results
03/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls"
03/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Announces U.S. Drug Enforcement Administration Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical"
02/28/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1 at the Society of Toxicology 2023 Annual Meeting"
02/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals, Inc., Registration Statement on Form S-3",
"MyMD Pharmaceuticals, Inc. 855 N. Wolfe Street, Suite 601 Baltimore, MD 21205"
02/23/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/14/2023 SC 13G/A Iroquois Capital Management, LLC reports a 6.5% stake in MyMD Pharmaceuticals, Inc.
02/03/2023 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/26/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy